Zestril Related Published Studies
Well-designed clinical trials related to Zestril (Lisinopril)
Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study protocol for a pilot randomised controlled trial. [2011.06.15]
Potential pharmacodynamic drug-drug interaction between concomitantly administered lisinopril and diclofenac sodium: a call for appropriate management in hypertensive osteoarthritic patients. [2011]
Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST): study
protocol for a pilot randomised controlled trial. [2011]
Carotid artery hemodynamics: observing patient-specific changes with amlodipine and lisinopril by using MR imaging computation fluid dynamics. [2010.12]
Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. [2010.09]
Specific and pronounced impacts of lisinopril and lisinopril plus simvastatin on erythrocyte antioxidant enzymes. [2010.02]
Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. [2010.01.15]
The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. [2009.11]
Pleural effusions, water balance mediators and the influence of lisinopril after completion Fontan procedures. [2009.07]
Irbesartan improves arterial compliance more than lisinopril. [2009]
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.05]
Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. [2008.02]
Bioequivalence evaluation of two brands of lisinopril tablets by in vitro comparative dissolution test and in vivo bioequivalence test. [2008]
A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. [2007.10]
Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients. [2007.06]
Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. [2007.03]
Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. [2007.02]
Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. [2007.01]
Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension. [2006.08]
A randomized, masked, cross-over trial of lisinopril for inflammatory macular edema. [2006.04]
Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. [2006.03]
Impact of chronic lisinopril therapy on left atrial volume versus dimension in chronic organic mitral regurgitation. [2006.02]
Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. [2006.02]
Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers. [2005.11]
Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. [2005.08]
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. [2005.06]
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. [2005.04.06]
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. [2005.02]
Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. [2005.01]
Clarithromycin suspension: bioequivalence studies on two different strengths. [2004.09]
Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. [2004.09]
Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). [2004.07]
Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. [2004.06]
Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. [2004.06]
Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. [2004.05]
Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. [2004.03.15]
Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients. [2004.01]
Evaluation of the bioequivalence and pharmacokinetics of two lisinopril tablet formulations after single oral administration in healthy volunteers. [2004]
Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. [2003.11]
A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. [2003.10]
Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. [2003.10]
Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. [2003.09.01]
Well-designed clinical trials possibly related to Zestril (Lisinopril)
Blood pressure control and cardiovascular outcomes in normal-weight, overweight,
and obese hypertensive patients treated with three different antihypertensives in
ALLHAT. [2014]
Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy
in diabetic nephropathy: a randomised clinical trial. [2014]
Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive
impairment: results of a pilot randomized clinical trial. [2013]
Clinical significance of incident hypokalemia and hyperkalemia in treated
hypertensive patients in the antihypertensive and lipid-lowering treatment to
prevent heart attack trial. [2012]
Pharmacotherapy review of chronic pediatric hypertension. [2011.10]
Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. [2011.07.26]
Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study. [2011.06]
Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. [2011.05]
[Merits of paracetamol in osteoarthritic hypertensive patients]. [2011.03]
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. [2011.02.10]
Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. [2011.02]
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. [2011.01.05]
Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. [2011]
Effect of statin therapy on disease progression in pediatric ADPKD: design and
baseline characteristics of participants. [2011]
Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in
relation to antihypertensive treatment: the genetics of hypertension associated
treatment study. [2011]
Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. [2010.12]
Importance of blood pressure control in left ventricular mass regression. [2010.11]
Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without beta-blockers. [2010.11]
Effects of ACE inhibitors on cardiac angiotensin II and aldosterone in humans: "Relevance of lipophilicity and affinity for ACE". [2010.11]
Brain function, cognition, and the blood pressure response to pharmacological treatment. [2010.09]
Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy. [2010.06]
Effect of self-measurement of blood pressure on adherence to treatment in patients with mild-to-moderate hypertension. [2010.03]
Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension. [2010.02]
Effect of self-measurement of blood pressure on adherence to treatment in
patients with mild-to-moderate hypertension. [2010]
Assessing medication adherence simultaneously by electronic monitoring and pill
count in patients with mild-to-moderate hypertension. [2010]
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. [2009.12]
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). [2009.11.24]
The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. [2009.11.18]
Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. [2009.10]
Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? [2009.09]
Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. [2009.07]
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. [2009.06]
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. [2009.05.11]
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. [2009.05]
Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. [2009.04]
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). [2009.02]
Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. [2009.01]
Controlling hypertension and hypotension immediately post stroke (CHHIPS)--a randomised controlled trial. [2009.01]
[The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ] [2009]
Brain imaging findings predict blood pressure response to pharmacological treatment. [2008.12]
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2008.11.25]
A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction. [2008.11]
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.10]
Cerebrovascular support for cognitive processing in hypertensive patients is altered by blood pressure treatment. [2008.07]
Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial. [2008.02]
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2008.01.28]
Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. [2008.01]
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]
Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study. [2007.11]
ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. [2007.07]
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study. [2007.04]
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. [2007.01]
Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. [2007]
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.11.13]
Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring. [2006.10]
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [2006.09]
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2006.09]
Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes. [2006.07]
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2006.05.09]
|
